ImmunovantInc Company Insiders
| IMVT Stock | USD 28.80 0.19 0.66% |
ImmunovantInc's insiders are aggressively selling. The analysis of the overall insider sentiment regarding ImmunovantInc suggests that vertually all insiders are panicking. ImmunovantInc employs about 164 people. The company is managed by 10 executives with a total tenure of roughly 383 years, averaging almost 38.0 years of service per executive, having 16.4 employees per reported executive.
ImmunovantInc's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-04-17 | Peter Salzmann | Disposed 34079 @ 29.06 | View | ||
| 2024-04-09 | Peter Salzmann | Disposed 4807 @ 31.18 | View | ||
| 2024-02-22 | Mark S Levine | Disposed 2134 @ 36.15 | View | ||
| 2024-01-26 | Mark S Levine | Disposed 3027 @ 37.92 | View | ||
| 2024-01-18 | William L Macias | Disposed 424 @ 41.03 | View | ||
| 2024-01-11 | Eva Renee Barnett | Disposed 3515 @ 41.83 | View | ||
| 2024-01-05 | Peter Salzmann | Disposed 3824 @ 38.59 | View | ||
| 2023-11-22 | Peter Salzmann | Disposed 16217 @ 32.78 | View | ||
| 2023-10-25 | Mark S Levine | Disposed 4107 @ 34.66 | View | ||
| 2023-10-19 | William L Macias | Disposed 530 @ 36.8 | View | ||
| 2023-10-10 | Eva Renee Barnett | Disposed 4557 @ 36.92 | View | ||
| 2023-10-05 | Julia G Butchko | Disposed 1735 @ 36.24 | View |
Monitoring ImmunovantInc's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ImmunovantInc |
ImmunovantInc Management Team Effectiveness
The company has return on total asset (ROA) of (0.2715) % which means that it has lost $0.2715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4451) %, meaning that it created substantial loss on money invested by shareholders. ImmunovantInc's management efficiency ratios could be used to measure how well ImmunovantInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to gain to -1.1 in 2024. Total Current Liabilities is likely to gain to about 52.3 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 317.6 M in 2024.Common Stock Shares Outstanding is likely to gain to about 148.6 M in 2024, whereas Net Loss is likely to drop (472.50) in 2024.
ImmunovantInc Workforce Comparison
ImmunovantInc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 5,403. ImmunovantInc holds roughly 164 in number of employees claiming about 3% of equities under Health Care industry.
ImmunovantInc Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunovantInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunovantInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ImmunovantInc insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 1.6 | 24 | 15 | 1,337,754 | 84,103 |
| 2023-12-01 | 0.0769 | 2 | 26 | 6,000,000 | 83,622 |
| 2023-06-01 | 4.4 | 22 | 5 | 2,040,481 | 11,504 |
| 2022-12-01 | 0.25 | 1 | 4 | 416,667 | 16,562 |
| 2022-09-01 | 3.6667 | 22 | 6 | 2,764,616 | 5,087 |
| 2022-03-01 | 2.0 | 12 | 6 | 1,328,483 | 262,856 |
| 2021-09-01 | 2.4 | 12 | 5 | 19,688,462 | 1,775,520 |
| 2019-12-01 | 21.0 | 42 | 2 | 41,309,844 | 10,000,000 |
| 2019-06-01 | 1.0 | 1 | 1 | 10,000,000 | 0.00 |
ImmunovantInc Notable Stakeholders
An ImmunovantInc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ImmunovantInc often face trade-offs trying to please all of them. ImmunovantInc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ImmunovantInc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andy Deig | Vice CEO | Profile | |
| MD MBA | Executive Board | Profile | |
| Jay Stout | Chief Officer | Profile | |
| Julia Butchko | Chief Officer | Profile | |
| Mark Levine | Chief Secretary | Profile | |
| Lauren MBA | Vice Marketing | Profile | |
| Chau MBA | Vice Relations | Profile | |
| Eva MBA | Chief Officer | Profile | |
| Christine Blodgett | Vice Resources | Profile | |
| MBA MD | Ex Board | Profile |
About ImmunovantInc Management Performance
The success or failure of an entity such as ImmunovantInc often depends on how effective the management is. ImmunovantInc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ImmunovantInc management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ImmunovantInc management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (1.16) | (1.10) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (1.16) | (1.11) |
The data published in ImmunovantInc's official financial statements usually reflect ImmunovantInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ImmunovantInc. For example, before you start analyzing numbers published by ImmunovantInc accountants, it's critical to develop an understanding of what ImmunovantInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ImmunovantInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ImmunovantInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ImmunovantInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ImmunovantInc. Please utilize our Beneish M Score to check the likelihood of ImmunovantInc's management manipulating its earnings.
ImmunovantInc Workforce Analysis
Traditionally, organizations such as ImmunovantInc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ImmunovantInc within its industry.ImmunovantInc Manpower Efficiency
Return on ImmunovantInc Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 21.1M | |
| Working Capital Per Employee | 2.2M | |
| Working Capital Per Executive | 36.1M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for ImmunovantInc Stock analysis
When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.